SAB Biotherapeutics, Inc.

NasdaqCM:SABS Stock Report

Market Cap: US$182.3m

SAB Biotherapeutics Valuation

Is SABS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SABS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate SABS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate SABS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SABS?

Key metric: As SABS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for SABS. This is calculated by dividing SABS's market cap by their current earnings.
What is SABS's PE Ratio?
PE Ratio9.7x
EarningsUS$18.74m
Market CapUS$182.33m

Price to Earnings Ratio vs Peers

How does SABS's PE Ratio compare to its peers?

The above table shows the PE ratio for SABS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15x
MCRB Seres Therapeutics
36.4x-41.08%US$259.0m
ABEO Abeona Therapeutics
2.8x17.59%US$227.6m
ICCC ImmuCell
17.9xn/aUS$42.9m
OPGN OpGen
2.9xn/aUS$50.8m
SABS SAB Biotherapeutics
9.7x-51.26%US$182.3m

Price-To-Earnings vs Peers: SABS is good value based on its Price-To-Earnings Ratio (9.7x) compared to the peer average (15x).

Price to Earnings Ratio vs Industry

How does SABS's PE Ratio compare vs other companies in the US Biotechs Industry?

10 CompaniesPrice / EarningsEstimated GrowthMarket Cap
NVAX Novavax
3x-61.28%US$1.03b
ABEO Abeona Therapeutics
2.8x17.59%US$227.60m
CHRS Coherus Oncology
2.2x-10.24%US$140.21m
OPGN OpGen
2.9xn/aUS$50.76m
SABS 9.7xIndustry Avg. 17.4xNo. of Companies10PE01632486480+
10 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: SABS is good value based on its Price-To-Earnings Ratio (9.7x) compared to the US Biotechs industry average (17.4x).

Price to Earnings Ratio vs Fair Ratio

What is SABS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SABS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio9.7x
Fair PE Ratio11.5x

Price-To-Earnings vs Fair Ratio: SABS is good value based on its Price-To-Earnings Ratio (9.7x) compared to the estimated Fair Price-To-Earnings Ratio (11.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SABS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.80
US$8.83
+132.46%
36.63%US$14.00US$5.00n/a6
Nov ’26US$3.25
US$8.83
+171.79%
36.63%US$14.00US$5.00n/a6
Oct ’26US$1.98
US$8.83
+346.13%
36.63%US$14.00US$5.00n/a6
Sep ’26US$2.08
US$9.20
+342.31%
37.27%US$14.00US$5.00n/a5
Aug ’26US$2.23
US$11.60
+420.18%
41.74%US$20.00US$7.00n/a5
Jul ’26US$1.76
US$11.40
+547.73%
40.62%US$20.00US$7.00n/a5
Jun ’26US$1.93
US$11.40
+490.67%
40.62%US$20.00US$7.00n/a5
May ’26US$1.70
US$10.60
+523.53%
48.33%US$20.00US$6.00n/a5
Apr ’26US$1.23
US$10.60
+761.65%
48.33%US$20.00US$6.00n/a5
Mar ’26US$1.71
US$12.40
+625.15%
53.64%US$25.00US$6.00n/a5
Feb ’26US$2.19
US$12.40
+466.21%
53.64%US$25.00US$6.00n/a5
Jan ’26US$3.79
US$12.40
+226.81%
53.64%US$25.00US$6.00n/a5
Dec ’25US$2.92
US$12.40
+324.66%
53.64%US$25.00US$6.00n/a5
Nov ’25US$3.88
US$12.40
+219.59%
53.64%US$25.00US$6.00US$3.255
Oct ’25US$2.60
US$12.75
+390.37%
58.00%US$25.00US$6.00US$1.984
Sep ’25US$2.94
US$12.75
+333.67%
58.00%US$25.00US$6.00US$2.084
Aug ’25US$2.77
US$13.00
+369.31%
65.57%US$25.00US$6.00US$2.233
Jul ’25US$3.04
US$13.00
+327.63%
65.57%US$25.00US$6.00US$1.763
Jun ’25US$2.64
US$15.50
+487.12%
61.29%US$25.00US$6.00US$1.932
May ’25US$4.10
US$15.50
+278.05%
61.29%US$25.00US$6.00US$1.702
Apr ’25US$4.29
US$20.00
+366.20%
50.00%US$30.00US$10.00US$1.232
Mar ’25US$4.41
US$20.00
+353.51%
50.00%US$30.00US$10.00US$1.712
Feb ’25US$5.90
US$20.00
+238.98%
50.00%US$30.00US$10.00US$2.192
Jan ’25US$6.88
US$20.00
+190.91%
50.00%US$30.00US$10.00US$3.792
Dec ’24US$9.40
US$20.00
+112.77%
50.00%US$30.00US$10.00US$2.922
Nov ’24US$10.00
US$25.00
+150.03%
20.00%US$30.00US$20.00US$3.882
US$8.83
Fair Value
57.0% undervalued intrinsic discount
6
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/20 07:57
End of Day Share Price 2025/11/20 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SAB Biotherapeutics, Inc. is covered by 8 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kumaraguru RajaBrookline Capital Markets
Keay NakaeChardan Capital Markets, LLC
Gum-Ming LoweCraig-Hallum Capital Group LLC